Cargando…

Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy

BACKGROUND: Thrombocytopenia can rapidly improve in chronic hepatitis C (CHC) patients receiving direct-acting antiviral agents (DAA). The role of baseline (BL) thrombopoietin (TPO) in this phenomenon is unclear. METHODS: From June 2016 to February 2019, a total of 104 CHC patients receiving DAA, wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Chun, Ko, Ping-Hung, Lee, Chi-Che, Tseng, Chih-Wei, Tseng, Kuo-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818549/
https://www.ncbi.nlm.nih.gov/pubmed/33478399
http://dx.doi.org/10.1186/s12876-021-01606-x
_version_ 1783638858582196224
author Chen, Yen-Chun
Ko, Ping-Hung
Lee, Chi-Che
Tseng, Chih-Wei
Tseng, Kuo-Chih
author_facet Chen, Yen-Chun
Ko, Ping-Hung
Lee, Chi-Che
Tseng, Chih-Wei
Tseng, Kuo-Chih
author_sort Chen, Yen-Chun
collection PubMed
description BACKGROUND: Thrombocytopenia can rapidly improve in chronic hepatitis C (CHC) patients receiving direct-acting antiviral agents (DAA). The role of baseline (BL) thrombopoietin (TPO) in this phenomenon is unclear. METHODS: From June 2016 to February 2019, a total of 104 CHC patients receiving DAA, with a sustained virologic response and BL thrombocytopenia, at Dalin Tzu Chi Hospital, were enrolled in this retrospective study. Significant platelet count improvement and platelet count improvement ratio were analyzed for correlation with BL TPO. RESULTS: This cohort included 40 men (38.5%). Seventy-two (69.2%) patients had advanced fibrosis. The platelet count [median (range)] increased from 110.5 (32–149) × 10(3)/µL at BL to 116.5 (40–196) and 118.0 (35–275) × 10(3)/µL at end of treatment (EOT) and 12 weeks after EOT (P12), respectively, (EOT vs. BL, P < 0.001; P12 vs. BL, P < 0.001). BL TPO was positively correlated with significant platelet count improvement (P < 0.001), platelet count improvement ratio at EOT (P = 0.004), and P12 (P < 0.001). The area under the receiver operating characteristic curve and optimal cutoffs (pg/ml) were 0.77 (95% confidence interval, 0.67–0.86) and 120, respectively, for significant platelet count improvement prediction. The sensitivity, specificity, and accuracy were 88.6%, 71.7%, and 78.8%, respectively. CONCLUSIONS: BL TPO level might be a useful marker for predicting significant platelet count improvement in thrombocytopenic patients after successful DAA therapy.
format Online
Article
Text
id pubmed-7818549
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78185492021-01-22 Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy Chen, Yen-Chun Ko, Ping-Hung Lee, Chi-Che Tseng, Chih-Wei Tseng, Kuo-Chih BMC Gastroenterol Research Article BACKGROUND: Thrombocytopenia can rapidly improve in chronic hepatitis C (CHC) patients receiving direct-acting antiviral agents (DAA). The role of baseline (BL) thrombopoietin (TPO) in this phenomenon is unclear. METHODS: From June 2016 to February 2019, a total of 104 CHC patients receiving DAA, with a sustained virologic response and BL thrombocytopenia, at Dalin Tzu Chi Hospital, were enrolled in this retrospective study. Significant platelet count improvement and platelet count improvement ratio were analyzed for correlation with BL TPO. RESULTS: This cohort included 40 men (38.5%). Seventy-two (69.2%) patients had advanced fibrosis. The platelet count [median (range)] increased from 110.5 (32–149) × 10(3)/µL at BL to 116.5 (40–196) and 118.0 (35–275) × 10(3)/µL at end of treatment (EOT) and 12 weeks after EOT (P12), respectively, (EOT vs. BL, P < 0.001; P12 vs. BL, P < 0.001). BL TPO was positively correlated with significant platelet count improvement (P < 0.001), platelet count improvement ratio at EOT (P = 0.004), and P12 (P < 0.001). The area under the receiver operating characteristic curve and optimal cutoffs (pg/ml) were 0.77 (95% confidence interval, 0.67–0.86) and 120, respectively, for significant platelet count improvement prediction. The sensitivity, specificity, and accuracy were 88.6%, 71.7%, and 78.8%, respectively. CONCLUSIONS: BL TPO level might be a useful marker for predicting significant platelet count improvement in thrombocytopenic patients after successful DAA therapy. BioMed Central 2021-01-21 /pmc/articles/PMC7818549/ /pubmed/33478399 http://dx.doi.org/10.1186/s12876-021-01606-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chen, Yen-Chun
Ko, Ping-Hung
Lee, Chi-Che
Tseng, Chih-Wei
Tseng, Kuo-Chih
Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title_full Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title_fullStr Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title_full_unstemmed Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title_short Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
title_sort baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis c patients after successful direct-acting antiviral agent therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818549/
https://www.ncbi.nlm.nih.gov/pubmed/33478399
http://dx.doi.org/10.1186/s12876-021-01606-x
work_keys_str_mv AT chenyenchun baselinethrombopoietinlevelisassociatedwithplateletcountimprovementinthrombocytopenicchronichepatitiscpatientsaftersuccessfuldirectactingantiviralagenttherapy
AT kopinghung baselinethrombopoietinlevelisassociatedwithplateletcountimprovementinthrombocytopenicchronichepatitiscpatientsaftersuccessfuldirectactingantiviralagenttherapy
AT leechiche baselinethrombopoietinlevelisassociatedwithplateletcountimprovementinthrombocytopenicchronichepatitiscpatientsaftersuccessfuldirectactingantiviralagenttherapy
AT tsengchihwei baselinethrombopoietinlevelisassociatedwithplateletcountimprovementinthrombocytopenicchronichepatitiscpatientsaftersuccessfuldirectactingantiviralagenttherapy
AT tsengkuochih baselinethrombopoietinlevelisassociatedwithplateletcountimprovementinthrombocytopenicchronichepatitiscpatientsaftersuccessfuldirectactingantiviralagenttherapy